Caris Life Sciences, Inc.

CAI

Explore Our Financial Data > Companies > Caris Life Sciences, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	CAI
CIK	0002019410
SIC	8071
Sector	Services
Industry Category	Healthcare
Industry Group	Services – Health

Contact

Address	750 W JOHN CARPENTER FREEWAY, SUITE 800, IRVING, TX, 75039
Website	www.carislifesciences.com
Phone	(866) 771-8946
CEO	David D. Halbert
Employees	1,769

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	N/A
Net Income	N/A
Net Income to Common	N/A
EPS	N/A

View All

Balance Sheet

Cash	N/A
Assets	N/A
Liabilities	N/A
Common Equity	N/A
Liabilities & Equity	N/A

View All

Cash Flow Statement

Net Income	N/A
Cash From Operating Activities	N/A
Cash From Investing Activities	N/A
Cash From Financing Activities	N/A
Change in Cash	N/A

View All

Calculations

NOPAT	N/A
EBITDA	N/A
Price to Earnings	N/A
Price to Book	N/A
ROE	N/A

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Should You Buy Caris Life Sciences Stock After the CAI IPO?

Shares of the company are up almost 30% from its IPO price.

Article Link

Caris Life Sciences indicated to open at $30, IPO priced at $21 per share

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering. Caris describes itself as a “patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare.” Caris has created the large-scale, multimodal clinico-genomic database and computing capability need

Article Link

The IPO Market Extends Its Comeback

Initial public offerings are like the ghosts in the 80s supernatural movie Poltergeist. Caris Life Sciences, a company that uses artificial-intelligence technology to help develop cancer treatments, and Slide, a specialty insurer focusing on property and casualty policies for customers in Florida and other states on the Atlantic coast, both debuted Wednesday and surged from their offering prices. Shares of Caris were up 25% from their offering price in mid-afternoon trading.

Article Link